Intra-Cellular Therapies Profit Margin

As of the most recent data (December 2024), ITCI shows a profit margin of -10.97%. That compares with -30.22% in the prior-year period — up 63.7% year over year. That is below the Healthcare sector average of 13.89%. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, ITCI's profit margin is now -10.97% (was -30.22%) — a 63.7% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Intra-Cellular Therapies is outperforming or lagging.

The Healthcare sector average profit margin is about 13.89%. Intra-Cellular Therapies is at -10.97%, which is lower that average. That is roughly 179.0% below the sector mean. Use the comparison chart on this page to see how ITCI stacks up against individual peers as well.

That compares with -30.22% in the prior-year period — up 63.7% year over year. Improvement over multiple periods is generally more meaningful than a single strong quarter. Compare Intra-Cellular Therapies with peers to see if the move is company-specific or sector-wide.

Besides this profit margin page, Stockcircle has Intra-Cellular Therapies's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect profit margin (currently -10.97%) with ownership activity and broader fundamentals.